2022 Boston Paris Biotechnology Summit™ Program
2022 Summit
The 2022 Summit will be in 2 parts: Virtual & In-Person
2022 Program
Virtual Boston Paris Biotechnology Summit™
on Thursday 29 September 2022
Funding in uncertain times, Legal Strategy, Talent Acquisition – 3 strategic points on your biotechnology company’s roadmap.
In-Person Summit on Friday 14 October 2022
1:00 PM to 5:00 PM US EST in Cambridge MA
From Clinical Trial Management to Commercial Success
Program – Virtual Summit – 29 September 2022
10:00 AM – 12:30 PM US EST – (16H00 – 18H30 France)
TALENT ACQUISITION & RETENTION
US LEGAL / REGULATORY STRATEGY
FUNDRAISING & MANAGEMET IN TIMES OF CRISIS
Virtual Summit Co-Chaired:
- Brian Malkin, JD, Partner, McDermott Will ad Emery.
- Shahin Gharakhanian, MD, Program Chair
Virtual Summit Moderators:
Jessica Foley, MS, RAC, Principal Consultant and Founder of Gaia Regulatory Sciences, LLC, CIC Cambridge, MA.
Frederic Jallat, PhD, Professor & Academic Director, ESCP Paris European Business School, Paris, FRANCE. Campuses: Berlin, London, Madrid, Paris, Turin, and Warsaw.
Mac Martirossian, CPA, Managing Director, MThree Advisory, Atlanta GA.
Karine Rossignol, Pharm D, CEO, SMART IMMUNE, developing a T-cell progenitor-based cell therapy platform, Paris, FRANCE.
TALENT ACQUISITION & RETENTION
Yvette CLELAND, CEO, CPL Life Sciences, London, UK. Yvette CLELAND, CEO CPL Life Sciences. CEO at CPL Life Sciences – Nominated by SIA as one of the top 50 most powerful women in staffing globally. CPL UK is a group of specialist talent businesses which service the professional services, science, technology, engineering, mathematics and health sectors across the UK. By Turnover, CPL UK currently sits firmly in the top 1% of all UK recruitment companies. Together they form the UK footprint for CPL Resources Plc which is one of the largest staffing companies in Europe. As a group CPL has been powering businesses by providing exceptional talent for over 30 years and have been listed on the London Stock Exchange since 1999.
Regis MULOT, Executive Vice President & Chief HR Officer, IPSEN, Paris, FRANCE. Regis MULOT EVP and Chief HR Officer at IPSEN has 30+ years of international Human Resources and business experience in Bio-pharma, transport, information technology, telecommunication, apparel, retail, e-commerce and business supplies multinational companies. Mr Regis MULOT has a successful track record of design, implementation & management of HR & CSR programs across North America, Europe, Africa, Asia, Pacific & Latin America in fast growing and changing environments.
US LEGAL / REGULATORY STRATEGY
Brian MALKIN, Partner, FDA and IP Practice, MWE: McDermott Will Emery, Washington DC, USA. Brian Malkin counsels pharmaceutical and biologic clients on Food and Drug Administration (FDA) regulatory matters and intellectual property (IP) law, with an emphasis on patent litigation. His practice at the intersection of FDA- regulated products and patent law makes him a valuable partner to drug manufacturers, biotechnology clients, medical device companies and cannabis companies as they develop new products and protect their innovations though life cycle management, bring their products to market and pursue transactional opportunities.
FUNDRAISING & MANAGEMET IN TIMES OF CRISIS
Marc DE GARIDEL, CEO, Cincor Pharma, Boston MA, USA. Marc de Garidel is the CEO of Cincor Pharma since July 1,2021, a private biotechnology company dedicated to developing a novel treatment against hypertension. Prior to joining CinCor, Mr. de Garidel served as CEO of Corvidia Therapeutics, a private Boston-based cardio-renal-focused clinical-stage company that was acquired by Novo Nordisk in 2020 for $2.1 Billion. Mr. de Garidel is Chairman of IPSEN Board of Directors. From 2010 to 2016, he served also as CEO and Chairman of IPSEN SA’s board of directors, where he led a significant transformation of the Company.
Thomas LINGELBACH, President & CEO, VALNEVA, FRANCE. Thomas Lingelbach was CEO of Intercell and founding CEO of Valneva, is an established vaccine industry leader with breadth of experience. Prior to Valneva, Thomas had senior & executive management roles with Intercell, Novartis and Chiron. During his 30 years in vaccines, he held a variety of positions from product development to commercialization with a strong emphasis on technical development & operations. In different capacities, he contributed to the successful development and licensure of more than ten vaccines. Thomas Lingelbach holds an engineering degree, specialized in bioprocess engineering from THM, GERMANY as well as Business Administration
Program – In-Person Summit – 14 October 2022
Pick up your badge at the Welcome Desk. Networking. Light Fare and Refreshments on site – Friday 14 October, 12 PM
1:00 PM – 5:00 PM US EST
From Clinical Trial Management to Commercial Success
A Boston Summit Workshop with Experts and <Master Class>
- Chair: Professor Marc Garnick, Harvard Medical School
- Co-Chair: Vanessa El Harrar, VP, PPD Biotech – [Thermo Fisher Group], Wilmington, NC, USA
Special Lecture: MONKEYPOX: State-of-our-Knowledge Professor Daniel Kuritzkes, Harvard Medical School, the Harriet Ryan Albee Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital, Boston MA. Program Committee discussant: Silvia Helou, MD, Infectious Diseases & Clinical Development, Greater New York, USA |
Clinical Development / Operations / Trials: state-of-the-Art Focus on BIOMARKERS: 2022 Update Biomarkers – Integration into Development Programs: Naji Gehchan, MD, Global Program Lead, Eli Lilly, Cambridge USA. Biomarkers – The Science: Anup Madan, Director of Biomarkers, PPD Biotech- [Thermo Fisher Group] Biomarkers and Artificial Intelligence: Ann Stowe, Associate Professor, CERELLUX and Dept of Neurology, University of Kentucky |
Focus on SAFETY IN Clinical Development: 2022 Update Focus Safety in Registational, Trials, Real world Data and Public Health: a new paradigm?: Biopharmaceutical Executive Speaker Delphine Saragoussi MD, MSc Public Health, Executive Director, PPD – [Thermo Fisher Group]. Program Committee discussant: Shahin Gharakhanian, MD, Cambridge MA, USA |
Putting it all in perspective: CLINICAL TRIALS: STATE-OF-THE-ART. Patients’ Perspective on Clinical Trials: Cecile Le Camus MD, Global Head of Hemophilia for RBD (Rare Blood Disorders), Medical Affairs Group, SANOFI-GENZYME, Cambridge MA, USA. 2022 Clinical Trial Status’ Overview by Session Chair/Co-chair: Marc B. Garnick, MD, Professor of Medicine, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston MA, USA Vanessa El Harrar MD, MPH, Vice President, Vaccines Business Strategy Lead, at PPD, Wilmington NC, USA |
First Boston Biotechnology Summit Lifetime Achievement Award: To Pravin Chaturvedi, PhD., CEO Oceanyx Pharmaceuticals; SAB, Napo Pharmaceuticals; Massachusetts Biotechnology Leader & Pioneer; Woburn, MA.Summit Special Advisor, and Chair Emeritus |
MASTER CLASS 2022: Is Your Product Commercially Viable? Corinne Le Goff, Boston MA, CEO Celsion Corp., NJ, USA. Named by Forbes Magazine 2021 as “Women changing the world”. Dr. Le Goff brings decades of global healthcare leadership experience to the Company across a range of therapeutic areas including oncology, vaccines, immunology, CNS and cardio-metabolism. |
You can check out the list of the 2022 Speakers as well as our International Program Committee under the appropriate tabs of this Website
5:00 PM EDT
Closing Remarks and Summit Adjourns
Register Today
Ready to register for the Boston Biotechnology Summit? Click the button below to get started with your registration process.
